UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.97 Million Stake in NewAmsterdam Pharma (NASDAQ:NAMS)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in NewAmsterdam Pharma (NASDAQ:NAMS ...
BioPharma Dive2d
NewAmsterdam drug shows ‘unexpected’ signs of protecting the heart in latest study
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
Investor's Business Daily on MSN2d
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 1-Year High on Analyst Upgrade
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) reached a new 52-week high during trading on Wednesday after Scotiabank raised their price target on the stock from $35.00 to $47.00. Scotiabank ...
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts
NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
The Pharma Letter2d
NewAmsterdam leaps on positive trial results
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
NewAmsterdam Pharma Says Main Goal In Phase 3 BROADWAY Study Achieved; Stock Up In Pre-market
NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, Tuesday announced positive topline data ...